Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Immatics N.V.NASDAQ: IMTX

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 15.0% from a year ago

Total equity stood at €456.28M at the end of Q1 FY2026, down 15.0% from a year earlier and down 5.7% from the prior quarter. Over 3 fiscal years it compounded at +31.4% a year.

Context

  • Total equity amounted to 83.9% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -15.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
€456.28M-5.7% QoQ
Last fiscal yearDec 2025
€483.89M-15.8% YoY
Year agoMar 2025
€536.61M-15.0% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.0%——
1 year-15.8%——
3-year CAGR+31.4%——
5-year CAGR——
10-year CAGR——

Total Equity history

EUR · from the balance sheet

Latest · FY2025
483.89M EUR
Year-over-year change
-15.8%
4-year CAGR
+111.8%

Total Equity vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -15.0% is the 7th highest of 11, against a peer median of -5.5%.
  • Total equity amounts to 83.9% of total assets for IMTX, versus a peer median of 73.1%.
IMTX Competitors
Total Equity for IMTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€17.75B EUR-4.1%-1.4%87.3%
LEGNLegend Biotech CorporationSep 2026$1.27B USD+25.9%+10.4%75.7%
JANXJanux Therapeutics, Inc.Mar 2026$941.54M USD-7.0%+44.0%91.6%
IMTXImmatics N.V.Mar 2026€456.28M EUR-15.0%+31.4%83.9%
IMCRImmunocore Holdings plcMar 2026$393.67M USD+4.0%+4.0%36.7%
ALLOAllogene Therapeutics, Inc.Mar 2026$278.88M USD-27.6%-24.0%70.4%
LYELLyell Immunopharma, Inc.Mar 2026$273.67M USD-18.7%-33.2%78.1%
TCRXTScan Therapeutics, Inc.Mar 2026$96.92M USD-53.9%+7.4%48.0%
DTILPrecision BioSciences, Inc.Mar 2026$76.1M USD+54.2%+15.1%52.9%
CLLSCellectis S.A.Mar 2026$59.92M USD-48.4%-15.5%20.7%
ATRAAtara Biotherapeutics, Inc.Mar 2026-$37.31M USD+32.2%—186.6%
Peer median (excluding IMTX) —-5.5%+4.0%73.1%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents132.99M148.52M218.47M236.75M345.77M
Short-term Investments12.12M213.69M207.42M367.7M123.37M
Net Receivables2.36M1.11M5.74M6.75M6.88M
Inventory00000
Other Current Assets950K13.84M7.12M6.31M14.86M
Total Current Assets152.21M377.15M449.37M629.56M503.79M
Property, Plant & Equipment (Net)20.49M26.49M57.06M63.71M54.87M
Goodwill00000
Intangible Assets1.32M1.63M1.52M1.63M1.58M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets636K2.55M2.02M1.25M1.85M
Total Non-current Assets22.44M30.67M60.6M66.59M58.3M
Total Assets174.65M407.82M509.97M696.15M562.1M
Account Payables3.01M4.03M7.67M10.11M339.86K
Short-term Debt00002.76M
Tax Payables1.76M7.72M7.86M3.77M0
Deferred Revenue50.4M64.96M100.4M35.91M15.81M
Other Current Liabilities28.04M17.88M20.48M4.77M2.81M
Total Current Liabilities95.15M106.45M156.55M67.99M42.99M
Long-term Debt00000
Deferred Tax Liabilities0005.8M3.81M
Deferred Revenue (Non-current)48.23M75.76M115.53M34.16M18.53M
Other Non-current Liabilities68K42K115.53M00
Total Non-current Liabilities55.44M88.2M128.33M53.32M35.21M
Total Liabilities150.58M194.66M284.88M121.3M78.2M
Common Stock629K767K847K1.22M1.34M
Retained Earnings(537.81M)(500.3M)(597.29M)(589.54M)(785.65M)
Accumulated OCI(3.95M)(1.48M)(1.64M)1.03M(8.59M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity24.06M213.16M225.08M574.84M483.89M
Total Debt9.85M14.56M15.4M16.2M15.63M
Net Debt(123.14M)(133.96M)(203.07M)(220.55M)(330.14M)

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.